Leukocyte migration inhibition assay in patients with prostate adenocarcinoma.
The leukocyte migration inhibition (LMI) assay was used to determine the cell-mediated immune reactivity of prostate cancer patients to putative tumor antigens present in potassium chloride extracts of surgically removed prostate tumor tissue. Using an extract prepared from prostate tumor tissue, inhibition of leukocyte migration was found more frequently in prostate tumor patients (61%) than in patients with benign prostate hyperplasia (37%), patients with nonprostate cancers (26%), or normal donors (10%). Control extracts prepared from normal prostate tissue, benign prostate hyperplasia tissue, and unrelated tumor tissue were statistically less reactive in the LMI assay than the prostate tumor extract when reacted against leukocytes from prostate tumor patients. These results suggest that the LMI assay might be potentially useful for measuring the tumor-directed, cell-mediated immune responses in patients with prostate cancer.
D000230:Adenocarcinoma / Q000097:blood / Q000276:immunology*; D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000276:immunology*; D002464:Cell Migration Inhibition; D006801:Humans; D007111:Immunity, Cellular; D007962:Leukocytes / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000276:immunology; D011470:Prostatic Hyperplasia / Q000276:immunology; D011471:Prostatic Neoplasms / Q000097:blood / Q000276:immunology*
D000951:Antigens, Neoplasm